Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...

Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for ...

A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, teeing the biotech to seek ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

Biomea Fusion is following through on a New Year’s resolution to become a metabolic-focused company. | Biomea Fusion is ...

Nineteen states and the District of Columbia have filed a new lawsuit against HHS Secretary Robert F. Kennedy Jr. in hopes of ...

Johnson & Johnson bought the full rights to a rare disease gene therapy a few years ago, but now the Big Pharma may be ...

Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...